USE OF FULVESTRANT FOR THE THERAPEUTIC CARE OF CENTRAL CORE DISEASE
Disclosed is an estrogen receptor antagonist of formula: for use in the treatment of a disease or disorder related to a decrease in calcium release between the sarcoplasmic reticulum and the cytosol, in particular the disease or disorder is a myopathy related to one or more mutations of the RyR1 gene or a myopathy linked to a decrease in calcium release, and more particularly central core disease. Also disclosed is a pharmaceutical composition including at least the oestrogen receptor antagonist of and at least one pharmaceutically acceptable excipient.
1 . A method of treatment of a disease or disorder related to a decrease in calcium release between the sarcoplasmic reticulum and the cytosol, comprising administering a therapeutically effective dose of estrogen receptor antagonist of formula:
to a patient in need thereof.
2 . The method of claim 1 , wherein the disease or disorder is a myopathy related to one or more mutations in the RyR1 gene or a myopathy related to a decrease in calcium release.
3 . The method of claim 1 , wherein the disease or disorder is central core disease.
4 - 5 . (canceled)
6 . A pharmaceutical composition comprising:
an estrogen receptor antagonist of formula:
at least one pharmaceutically acceptable excipient.
7 . The pharmaceutical composition according to claim 6 , wherein the composition is suitable to be administered to a subject in a therapeutically effective amount.
8 . The pharmaceutical composition according to claim 6 , wherein the composition is suitable for use as a medicine.
9 . The method of claim 2 , wherein the disease or disorder is central core disease.
10 . The pharmaceutical composition according to claim 7 , wherein the composition is suitable for use as a medicine.